You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:


Last Updated: April 3, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,617,598

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,617,598 protect, and when does it expire?

Patent 8,617,598 protects AFINITOR DISPERZ and is included in one NDA.

Protection for AFINITOR DISPERZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-eight patent family members in thirty countries.

Summary for Patent: 8,617,598
Title:Pharmaceutical compositions comprising colloidal silicon dioxide
Abstract: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
Inventor(s): Haeberlin; Barbara (Munchenstein, CH), Kramer; Andrea (Reute, DE), Heuerding; Silvia (Basel, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:13/489,396
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,617,598
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Formulation; Process;

Drugs Protected by US Patent 8,617,598

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharm AFINITOR DISPERZ everolimus TABLET, FOR SUSPENSION;ORAL 203985-001 Aug 29, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis Pharm AFINITOR DISPERZ everolimus TABLET, FOR SUSPENSION;ORAL 203985-002 Aug 29, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis Pharm AFINITOR DISPERZ everolimus TABLET, FOR SUSPENSION;ORAL 203985-003 Aug 29, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,617,598

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0123400.4Sep 28, 2001

International Family Members for US Patent 8,617,598

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 036643   Start Trial
Argentina 097341   Start Trial
Austria 485813   Start Trial
Brazil 0212922   Start Trial
Brazil PI0212922   Start Trial
Canada 2458455   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.